Evaluation Of Automatic Class III Designation (De Novo) Summaries

• Skip to main content
• Skip to FDA Search
• Skip to in this section menu
• Skip to footer links

In this section: CDRH Transparency

• CDRH Transparency
  • Overview of CDRH Transparency
  • Total Product Life Cycle for Medical Devices
  • CDRH Transparency: Premarket Submissions
  • CDRH Transparency: Postmarket Performance and Safety
  • CDRH Transparency: Compliance & Enforcement

1. Home
2. About FDA
3. FDA Organization
4. Center for Devices and Radiological Health
5. CDRH Transparency
6. Evaluation of Automatic Class III Designation (De Novo) Summaries

1. CDRH Transparency

• CDRH Transparency
  • Overview of CDRH Transparency
  • Total Product Life Cycle for Medical Devices
  • CDRH Transparency: Premarket Submissions
  • CDRH Transparency: Postmarket Performance and Safety
  • CDRH Transparency: Compliance & Enforcement

The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the De Novo classification option as an alternate pathway to classify novel medical devices that had automatically been placed in Class III after receiving a "not substantially equivalent" (NSE) determination in response to a premarket notification [510(k)] submission. Section 513(f)(2) of the FD&C Act was amended by section 607 of the Food and Drug Administration Safety and Innovation Act (FDASIA), on July 9, 2012, to allow a sponsor to submit a De Novo classification request to the FDA for without first being required to submit a 510(k).

There are two options for De Novo classification for novel devices of low to moderate risk.

• Option 1: Any person who receives an NSE determination in response to a 510(k) submission may, within 30 days of receipt of the NSE determination, submit a De Novo request for the FDA to make a risk-based evaluation for classification of the device into Class I or II.
• Option 2: Any person who determines that there is no legally marketed device upon which to base a determination of substantial equivalence may submit a De Novo request for the FDA to make a risk-based classification of the device into Class I or II, without first submitting a 510(k) and receiving an NSE determination.

Devices that are classified through the de novo process may be marketed and used as predicates for future 510(k) submissions.

Since 2010, the FDA has released summary documents for devices classified through the De Novo process. The De Novo summary is intended to present an objective and balanced summary of the scientific evidence that served as the basis for the decision to grant a De Novo request. The De Novo summary also serves as a resource regarding the types of information necessary to support substantial equivalence for device manufacturers that may wish to use the device as a predicate for future 510(k) submissions.

Additional Information

• Device Advice: De Novo Classification Requests
• Search the De Novo database

• Content current as of:

  05/29/2024

• Regulated Product(s)

  • Medical Devices

Feedback Back to Top